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Introduction
Despite the high frequency in which smooth muscle
myomas develop, the knowledge on their development
and growth remains incomplete. On the basis of multi-
ple studies, including cytogenetic ones, every smooth
muscle myoma is thought to represent a product of
clonal expansion of a single myocyte [1,2]. Similarly
to the situation noted in other tumours, most probably
genetically sensitive sites exist, the mutation of which
leads to loss of control over smooth muscle prolifera-
tion and to a transformation of a smooth muscle cell to
yield a common phenotype of a smooth muscle
myoma cell.
The neoplastic transformation of smooth muscles
to a smooth muscle myoma probably involves somatic
mutations of genes important in proliferation and
apoptosis of normal myometrium and in complex
interactions between sex steroids and growth factors
[3,4]. The observations have provided investigators
with an insight into myoma pathophysiology and have
yielded the first key to recognise growth potential of
the ovarian steroid-dependent tumours. Nevertheless,
the role of steroids and of other growth factors in initi-
ation and growth of the tumours still remains only par-
tially recognised. 
A marked number of experimental and clinical
data indicate that estrogen stimulates growth of uter-
ine smooth muscle myomas [5,6]. In the middle of
1970-ties, detection that smooth muscle myomas
carry estrogen receptors additionally backed up the
hypothesis that smooth muscle cell myomas at least
partially are dependent on estrogen [7]. It was also
noted that, as compared to normal myometrium,
smooth muscle cell myomas contained increased lev-
els of the receptors [8,9].
In 1994, Bulun et al. [10] detected presence of aro-
matase in smooth muscle cell myomas. As compared
to the surrounding myometrium, smooth muscle cell
myomas contained eleveted levels of aromatase and
were able to synthesize estrogen [10,11] while tissue
concentrations of estrogen were augmented in smooth
muscle cell myomas as compared to the surrounding
myometrium [12,13]. In addition, in vitro experiments
proved that estrogen synthesized in smooth muscle
cells in a culture was sufficient to support proliferation
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in an intracrine manner, since stimulation of aromatase
activity increased cell proliferation while an aromatase
inhibitor reduced the proliferation [11].
Studies on correlation between levels of aromatase
mRNA disclosed a positive trend between the levels
and progressing age of the patients. This would sug-
gest that local expression of aromatase may be a sig-
nificant variable which determines availability of
estrogen for myoma tissues even if the levels of circu-
lating estrogen are markedly lowered in peri- and post-
menopausal women. 
Determination of aromatase expression in the
tumour cells and cells of other estrogen-dependent
tumours is significant for disclosing pathogenesis of
the tumours and for defining potential directions of
their therapy. An increasing number of studies sug-
gests that in women of post-menopausal age estrogens
localised in tumour cells originate from in situ aroma-
tization in the pathologically changed tissue and they
act there as a mitogenic factor, promoting tumour
growth independently of estrogen concentrations in
the serum.
Clinical studies of the earlier operated women
demonstrate frequent development of novel neoplastic
foci in myometrium. This study aimed at an attempt to
demonstrate possible presence of potentially neoplas-
tic cells in the margins of healthy tissue, which was
removed together with the primary tumour. Our earli-
er studies [14] indicate, that healthy myometrium
taken 4 cm from myomas demonstrated active telom-
erase like tumor cells.
Thus the aim of our study is to detect telomerase
expression in myoma cells and demonstrate its activi-
ty in healthy myometrium in relation to the distance
from pathological lesion, assuming low activity of the
enzyme in normal cells and markedly higher one in
myoma cells.
Materials and methods
Human material. Recruitment of patients, clinical studies and
hormonal tests will be conducted in the Chair and Department of
Gynaecological Endocrinology, Medical University of Silesia in
Katowice while enzymatic and protein studies will be executed in
the Department of Proteomics. 
The studies were conducted on 40 patients with myomas, at the
reproductive age (below 45th year of age, FSH <30 mIU/ml; sam-
ples were taken in follicular phase of menstrual cycle) and 40
patients with myomas in the perimenopausal age (45-55 years of
life, FSH >30 mIU/ml). Inclusion criteria will involve myomas
detected by USG, qualification of the patient to hysterectomy,
informed consent to the planned studies. The exclusion criteria will
include: therapy with any drugs, including hormonal drugs in the
minimum of 3 months before inclusion to the studies, neoplastic
disease, endometrial hypertrophy, metabolic and systemic distur-
bances, nicotinism. 
Myometrial samples, for use as health controls were taken
from 10 young women (<40 years old) undergoing hysterectomies
for ovary tumors and 10 older women (>52 years old) undergoing
hysterectomies for uterine prolapse.
The material for studies was sampled intraoperatively. Samples
of myoma 1 × 1 cm and samples of a similar size from healthy
myometrium at the distance of at least 4 cm each were taken.
Before isolation of myometrium samples the patients were
informed on the aim of the studies. The planned investigative pro-
cedures were approved by the Medical Bioethical Commission.
Characteristics of studied groups.
Group 1. Myometrium of menstruating women, in whom hys-
terectomy was performed for reasons other than uterine
leiomyomas; the 10 patients represented the lesion-free
control.
Group 2. Leiomyomas of < 3 cm in diameter, sampled from uteri
of menstruating women (n=20 women).
Group 3. Myometrium of menstruating women, sampled at the
distance of not less than 4 cm from margins of a small
leiomyoma (n=20 women; autologous control).
Group 4. Leiomyomas of > 5 cm in diameter, sampled from uteri
of menstruating women (n=20 women).
Group 5. Myometrium of menstruating women, sampled at the
distance of not less than 4 cm from margins of a large
leiomyoma (n=20 women; autologous control).
Group 6. Myometrium of non-menstruating women, in whom
hysterectomy was performed for reasons different than
uterine leiomyomas (n=10 women; lesion-free control).
Group 7. Leiomyomas of < 3 cm in diameter, sampled from uteri
of non-menstruating women (n=20 women).
Group 8. Myometrium of non-menstruating women, sampled at
the distance of not less than 4 cm from margins of a
large leiomyoma (n=20; autologous control).
Group 9. Leiomyomas of > 5 cm in diameter, sampled from uteri
of non-menstruating women, (n= 20 women).
Group 10. Myometrium of non-menstruating women, sampled at
the distance of not less than 4 cm from margins of a
large leiomyoma (n=20 women, autologous control).
Immunohistochemistry. Tissue specimens were fixed in 4%
buffered paraformalgehyde solution, dehydrated and than embed-
ed in paraffin. Section (5 μm) were mounted onto silane-coated
slides. Samples were de-waxed, rehydrated and endogenous per-
oxidase activity quanched using 1,5% (v/v) solution H2O2 in
methanol for 10 min and then washed in PBS-Tween 20 (0,05%
v/v) and blocked with normal goat serum for 30 min. The sections
were futher blocked with avidin-biotin-blocking solution accord-
ing to the manufacturer's instruction. After this the slides were
incubated with rabbit anti-aromatase polyclonal antibody (Abcam)
in a humidified chamber for 22 h at 4°C. After washing in PBS-
Tween 20 sections were incubated with biotinylated goat anti-rab-
bit immunoglobulins (Vector Laboratories Inc.) for 30 min. After
washing, the sections were incubated with horseradish-peroxidase
avidin-biotin complex (Vector) for 30 min. The bound antibodies
were visualised with diaminobenzidine (DAB) and H2O2 in PBS,
pH 7,5 according to supplier's instructions (Vector). Counterstain-
ing of nuclei was performed by dipping the slides in Gill's hema-
toxilin. For negative controls rabbit IgG were used. 
In each positively stained cell, the intensity of staining was
measured as the optical density of the reaction product, with the
program KS 100 VIDAS video image analyzer served by IBAS 2.5
system and a Panasonic digital camera. For each analyzed area,
173 × 130 μm average optical density per unit area was calculated.
Finally, the arithmetic mean and standard deviation was calculated.
Western blotting. Tissue samples (~500 mg) were homogenized
in 7 ml buffer containing 10 mM Tris-HCl (pH 7.5), 150 mM KCl,
1 mM EDTA, and 1 mM dithiothreitol. Homogenates were cen-
trifuged at 1,000 × g for 10 min. The supernatant was then cen-
trifuged for 60 min at 105,000 × g, and resultant microsomal pel-
lets were resuspended in 200 μl buffer containing 50 mM Tris-HCl,
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20% glycerol, 1 mM EDTA, and 1 mM dithiothreitol, then frozen
in liquid nitrogen. 25-μg sample of microsomal protein was loaded
into each lane, electrophoresed on a 10% SDS-polyacrylamide gel,
and electroblotted onto a polyvinylidene difluoride membrane
using a wet electroblotter. After blocking, incubation was carried
out with antiaromatase antibody (1:1000 Abcam) at 4 C for 20 h in
TBS-T solution (20 mM Tris, 137 mM NaCl, and 0.1% Tween-20,
pH 7.6). After extensive washing, blots were incubated with
biotinylated anti-rabbit IgG made in goat (Vectastain ABC-AmP
Vector Laboratories, Inc.) for 30 min and with streptavidin and
biotinylated alkaline phospatase complex for 30 min and devel-
oped using a BCIP/NBT Alkaline Phosphatase Substrate Kit (Vec-
tor Laboratories, Inc.).
Statistical analysis. Normal distribution of the data was confirmed
by the Kolmogorov-Smirnov test. Results are presented as a mean
± standard deviation. The Student's t-test or the Mann-Whitney U-
test were performed where appropriate. The differences were
regarded significant at p ≤ 0.05 level.
Results
Immunohistochemistry
Young women. Optical density of cells with expres-
sion of the evaluated protein reflects concentration of
the immunocytochemical reaction product. Aro-
matase expression level was demonstrated to signifi-
cantly increase in small myomas of young women, in
which the density amounted to around 190%, in relat-
ed to healthy myometrium as a control value (Fig. 1;
2, A and B). An analogous analysis performed at the
periphery of the small myomas demonstrated that
expression of the enzyme was also higher than in the
control, reaching 210% of the control level (Fig. 2, A
and C). Analysis of the data showed that aromatase
expression at the periphery of myomas reached
almost 110% of the values observed in the myoma
itself.
Comparison of aromatase expression in large
myomas showed that the enzyme expression reached
280% of the control group level (Fig. 2, A and D).
Unlike to the small myomas, aromatase expression
measured at the periphery was slightly lower than in
the myoma and comprised 200% of the control level
(Fig. 2, A and E). Thus, in this case aromatase expres-
sion at the periphery of large myomas was lower than
that in the myoma and it amounted to 70% of the val-
ues observed in the myoma itself.
Quantitative analysis of aromatase expression in
uterine myomas of young women disclosed lower
expression of aromatase in small as compared to large
myomas. At the periphery of myomas aromatase
expression proved to be slightly lower in direct vicini-
ty of large myomas, as compared to vicinity of small
myomas, amounting to, approximately, 95% of the lat-
ter level.
Women in a perimenopausal age. Evaluation of aro-
matase level in the studied uterine structures showed
that in women in a perimenopausal age optical density
of the reaction product in small myomas reached the
level of almost 200% of the control level (Fig. 1; 2, F
and G). The analysis related to periphery of the myoma
showed the enzyme expression level also higher than
in the control (230% of the control level; Fig. 2, F and
H). Aromatase expression at the periphery of myoma
was documented to be lower than the value observed
in the myoma itself (115%).
Analysis of optical density in large myomas with
aromatase expression demonstrated expression levels
amounting to 190% of the control value (Fig. 2, F and
I). Aromatase activity measured at the periphery of a
large myoma was higher than the control value (Fig. 2,
F and J). Aromatase expression at the periphery of a
large myoma was only slightly lower than in the
myoma itself, amounting to around 90% of the value
noted in the myoma.
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Fig. 1. Quantitative evaluation of aro-
matase expression. Date shown represent
mean ± SD. Differences in aromatase
expression: * – in reproductive age
women and perimenopausal age women; a
– in small myomas and healthy myometri-
um; b – in periphery of small myomas and
healthy myometrium; c – in large myomas
and healthy myometrium; d – in periphery
of large myomas and healthy myometri-
um; e – in small myomas and its periph-
ery; f – in small myomas and its periphery,
are statistically significant. There is
Western blot analysis of aromatase in
myometruim and leiomyoma tissue from
reproductive age women and peri-
menopausal age women under the figure.
Samples (25 μg/lane) were elec-
trophoresed, blotted and aromatase was
detected (see Materials and methods).
In women of perimenopausal age aromatase
expression in large myomas proved to be lower than in
small myomas, reaching around 95% of the level typi-
cal of small myomas. Quantitative analysis of aro-
matase expression in the myomas of perimenopausal
women indicated lower expression in large myomas
than in small one (95%). The expression its enzyme
measured at the periphery of large myomas was lower
than at the periphery of small myomas (75%).
Effect of patient's age. Comparison of the content of
aromatase expression product demonstrated the lower
level of the enzyme in control samples isolated from
young women than in samples originating from
women in a perimenopausal age (Fig. 1). In small
myomas originating from women in a perimenopausal
age aromatase expression level reached 120% of the
value demonstrated in small myomas originating from
the group of young women. If aromatase expression
was evaluated at the periphery of small myomas in the
two age groups, its higher level was disclosed in older
women, in whom the level reached 127% of the value
noted in young women. 
Analysis of the enzyme expression in large
myomas showed its lower level in women in a peri-
menopausal age, in whom it amounted 80% of the
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Fig. 2. Immunohistochemical staining of
uterini samples from reproductive (A-E)
and perimenopausal age women (F-J)
with rabbit anti-aromatase polyclonal
antibodies. A and F – healthy myometri-
um, B and G – small myomas, C and H –
periphery of small myomas, D and I –
large myomas, E and J – periphery of
large myomas.
level observed in young women. The level of reaction
product measured at the periphery of large myomas
was the same lower in older women like in the young
women. 
Western blot analysis
Comparing expression of aromatase in myometrium of
females at various age it was found slightly higher in
samples originating from perimenopausal females
although the difference failed to be significant. 
For a better and more clear evaluation of changes in
aromatase expression a quantitative analysis was con-
ducted exclusively in the same age groups, accepting
as the 100% value the level of the expression noted in
the pure control.
The detected aromatase expression level in small
myomas sampled from uteri of young women was
clearly higher than in the control, amounting to 165%,
and the difference was significant. Even higher expres-
sion level was observed in large myomas, in which
expression level of the protein amounted to 210% of
the control level (Table 1; see also Fig. 1). 
The level of aromatase expression measured at the
periphery of myomas originating from uteri of young
women was higher than that in the control, amounting
to 185% and 180%, respectively, in small and large
myomas.
In analysis of aromatase expression levels in the
myomas and in their direct vicinity, in the cases of both
small and large myomas the levels showed no signifi-
cant differences. Analysis of changes in aromatase
expression in uteri of postmenopausal women the
course of the changes manifested a similar course to
that noted in young women. The aromatase expression
level in small myomas isolated from uteri of peri-
menopausal women was higher than in the control,
amounting to 175%, and the change was statistically
significant. The aromatase expression level observed
in large myomas in the samke age group was slightly
lower and amounted to 160% of the control level. 
Aromatase expression measured at the periphery of
the myomas was also higher than that seen in the con-
trol. In cases of small and large myomas the levels
amounted to 205% and 150%, respectively (Table 1;
see also Fig. 1) and the differences proved to be sig-
nificant.
Evaluating aromatase expression levels in myomas
and the surrounding myometrium in the older age
group the aromatase expression in small myomas
proved to be significantly lower than in the surrounding
myometrium. In large myomas and their surrounding
myometrium the difference proved to be insignificant.
Discussion
Smooth muscle myomas of the uterus are the most fre-
quent tumours of the female genital tract. In as many
as 75% cases histerectomy preparations following sur-
gery conducted for various reasons were found to con-
tain uterine smooth muscle myomas [15]. The
obtained clinico-pathological data, involving at least a
few hundreds of problematic cases of uterine smooth
muscle myomas and other detailed studies conducted
by the same group of pathologists, provide at present
the principal source of data for clinical management of
the difficult group of tumours [16,17].
Determination of aromatase expression in cells of
myomas and other estrogen-dependent tumours seems
significant from the point of view of pathogenesis of
the tumours and potential directions of therapy. The
increasingly numerous studies suggest that in women
of postmenopausal age estrogens localised in tumour
cells originate from in situ aromatization in the patho-
logically altered tissue and that they act locally as a
mitogenic factor, facilitating tumour growth independ-
ently of estrogen concentrations in the serum. 
In our studies myometrium sampled from women
in whom no myomas were detected has been found to
express aromatase. Its level has been low but similar in
the two age groups, of young women and women in
the perimenopausal age. This indicates that upon
access of androgens they can be aromatized to estro-
gens in the uterus. This may result in a locally aug-
mented level of estrogens in myometrium, the level
which may exceed physiological concentrations. 
The observations are not fully confirmed by reports
of other authors: it some of the reports slightly distinct
501Aromatase expression in myomas and myometriums
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2009:47(3): 501 (497-504) 
10.2478/v10042-009-0105-0
Table 1. Level of aromatase protein in uterus tissue samples from myometrium and leiomyomas from young and perimenopausal age
women. Quantitative analysis indicated, that aromatase level in myometrium perimenopausal age women is 110% those in young women.
Differences in aromatase expression: * – in reproductive age women and perimenopausal age women; a in small myomas and healthy myometrium; b in
periphery of small myomas and healthy myometrium; c in large myomas and healthy myometrium; d in periphery of large myomas and healthy myometri-
um; e in small myomas and its periphery, are statistically significant for p=0.05.
results have been presented. Their authors stress that
smooth muscle myoma tissue becomes a source of
estrogen when it is exposed to endogenous sex
steroids. The smooth muscle myoma tissue contains its
own aromatase, a microsomal enzyme, which cat-
alyzes conversion of androgens to estrogen even if this
cannot happen in a normal myometrium [10]. The
exogenous estrogen, produced by smooth muscle
myomas, probably promotes growth in an autocrine or
intracrine manner [11]. Production of estrogen in
smooth muscle myomas is inhibited by treatment with
GnRH agonist in situ [18] and in vivo [19] due to inhi-
bition of aromatase activity. Shozu et al. [20] found
that size of smooth muscle myoma was directly relat-
ed to expression of aromatase mRNA in various
smooth muscle myomas within the same uterus. The
correlation could not be observed for aromatase
mRNA levels noted in distinct patients, carrying
smooth muscle myomas of a significant size [20]. In a
smooth muscle myoma tissue conversion of estrone to
estradiol is three-fold more intense than in a respective
myometrium, which corresponds to higher expression
of mRNA for 17β-hydroxysteroid dehydrogenase
(HSD) type I [20]. The enzyme catalyzes reciprocal
conversion of adrostenedione and testosterone, as well
as of estrone and estradiol and, together with aro-
matase, plays a significant role.
In postmenopausal women, circulating estrogens
originate, first of all, from peripheral conversion of
androgens synthesized both in ovaries and in
suprarenal glands. Such a conversion takes place
mainly in peripheral tissues but, as proven by results of
studies on expression of aromatase gene, local synthe-
sis of androgens occurs also in endometrial adenocar-
cinoma even if the amount of the hormone produced
there is not sufficient to increase estrogen pool in the
peripheral blood. Even if no direct proof is available
for the role of estrogen in in situ growth of myoma
cells, the experiment with use of a circulating
androstenedione as a substrate showed that myoma
cells are capable of synthesizing sufficient amounts of
estrogens to promote their own growth [18]. 
In women at their reproductive age the amount of
circulating estrogen, produced by ovaries, is substan-
tial as compared to the in situ synthesized estrogen.
Thus, estrogen in situ may belong to factors which are
important for growth of myoma cells. On the other
hand, following cessation of ovarian follicle growth
the in situ produced estrogen may represent its only
available source for myoma tissue in postmenopausal
women. Since blood androstenedione levels (5-10
nmol/l) in women at early menopause continue to per-
sist close to KM value for aromatase, significant
amounts of estrogen can be synthesized in situ taking
advantage of plasma androstenedione [11]. Thus,
estrogen produced in situ may prevent abrupt regres-
sion of myoma cells due to the complete disappearance
of the ovarian estrogen [18]. In fact, most of myomas
demonstrate no perceptible traits of regression in the
course of the first 6 months of natural menopause
despite the abrupt decrease in plasma estradiol con-
centration and the regression is clearly slower in
women treated with GnRH agonists. Size of a myoma
may decrease with age but the amount of estrogen
which is produced in situ does not decrease until
suprarenal production of androstenedione becomes
reduced.
The above considerations acquire an additional
dimension in patients with uterine myomas. In such a
case, particular attention should be devoted to results
pertaining aromatase activity in tests performed on
samples from young women. In this age group we
have noted a particularly strongly expressed aromatase
activity, first of all in large myomas. Such a situation
may point to severe consequences for health of the
patients. The mechanism due to which myoma main-
tains high level of aromatase expression still remains
unknown. A few genes demonstrate overexpression in
myomas, as compared to the surrounding myometrium
[21]. Some of the genes are stimulated by estrogen and
manifest expression level normal for myometrium in
conditions of hypoestrogenism, induced by GnRH
agonists. Although treatment with GnRH agonists
decreases also expression of aromatase in myomas, the
estrogen-linked control does not seem to be related to
aromatase since treatment with estradiol does not
affect aromatase expression level in cultures of myoma
cells [18]. The only suggestion which can be put for-
ward as to the mechanisms maintaining aromatase
overexpression reflects the fact that no significant dif-
ferences have been noted in aromatase expression
between myoma cells and ex vivo cultured myometrial
cells. When myoma cells become isolated from tissue
and placed in a culture, aromatase expression decreas-
es by 5-20% as compared to the values noted in the tis-
sue[10,18,22]. In an ex vivo culture both basal and
induced levels of expression are identical in myoma
cells and in myometrium originating from the same
uterus. On the other hand, supplementation with
myoma homogenate recovered aromatase expression
in myoma cells, which reached levels typical for the
tissue [22]. The results are consistent with the obser-
vation that myoma cells preserve the ability to express
aromatase in response to an adequate stimulus in the
tissue and reduce the expression to basal levels when
the stimulus is removed, as it happens in an ex vivo
culture. Already in preliminary discussions on factors
which might modify the expression, IL-1b secreted by
myoma cells represented the candidate for such an in
vivo stimulating factor. 
Another potential explanation for aromatase over-
expression in myomas involves activity of mitogen-
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activated protein kinase (MAPK), stimulated by a
variety of extracellular signals, including growth fac-
tors. Activity of MAPK is indispensable for a full
induction of mRNA for aromatase and for its activity
[23]. As compared to myometrium, expression of
MAPK and its activity increase in the myoma tissue,
probably due to differences in expression of the
extracellular matrix between the tissues [24]. Bypass-
ing certain details, it may be accepted that increase in
MAPK activity may participate in aromatase overex-
pression in myomas.
Activity of aromatase in myoma tissue has been
reported in literature of the subject Nevertheless, dis-
tinct opinion can be encountered on presence of the
enzyme in endometrium involved by the pathological
process. Sumitani et al. [11] demonstrated low
amounts of mRNA for aromatase gene in endometrium
of myomatous uteri. They demonstrated also that
expression of CYP19 gene within uterine myomas was
higher than in the surrounding myometrium and
endometrium. Therefore, it seems possible that
myomas, similarly to other tumours, release factors
which promote local steroidogenesis. The question
arises if demonstration of local steroidogenesis in
endometrium of myomatous uteri does not represent a
prognostically negative index, pointing to the risk of
neoplastic transformation in the tissue. Clinical studies
indicate that uterine adenocarcinoma in 30% coincides
with myomas. The obtained results provoke further
investigations, aimed at clarification of aromatase role
in pathology of the disease.
Literature reports on the subject are very scant. In
the innumerous reports on local synthesis of estrogens
in uterine myomas an attempt has been made to
resolve whether aromatase present in uterine myomas
plays an important role in their growth and whether
myomas synthesize sufficient amounts of estrogens to
promote myoma growth. Myoma cells are thought to
be capable of synthesizing sufficient amounts of estro-
gens and local aromatization in myoma tissues is
thought to be responsible for the cell growth-promot-
ing affect.
Continuing the analysis of aromatase role one
should keep in mind our important observation that
expression of aromatase has been evident in myome-
tria obtained from patients with myomas. Although the
expression level has been lower than in myomas, it has
been clearly higher than in normal myometria. It
should be noted that the samples have been isolated
outside of the so called surgical safety margin and,
thus, they have represented uterine region in which no
myomatous relapse should develop. Our studies have
demonstrated that in such a region aromatase expres-
sion level in favourable conditions has been sufficient-
ly high to promote de novo development of a myoma.
The problem of how far from the neoplastic lesion aro-
matase expression is significantly elevated remains
unsolved. This will require further arduous investiga-
tions.
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